83 related articles for article (PubMed ID: 35681259)
21. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and in vitro anticancer research of novel tetrandrine and fangchinoline derivatives.
Gao XZ; Lv XT; Zhang RR; Luo Y; Wang MX; Chen JS; Zhang YK; Sun B; Sun JY; Liu YF; Liu C
Bioorg Chem; 2021 Apr; 109():104694. PubMed ID: 33601141
[TBL] [Abstract][Full Text] [Related]
23. Construction of novel mRNA-miRNA-lncRNA regulatory networks associated with prognosis of ovarian cancer.
Gao L; Li X; Nie X; Guo Q; Liu Q; Qi Y; Liu J; Lin B
J Cancer; 2020; 11(23):7057-7072. PubMed ID: 33123295
[No Abstract] [Full Text] [Related]
24. Three Genes Predict Prognosis in Microenvironment of Ovarian Cancer.
Guo Y; Wang YL; Su WH; Yang PT; Chen J; Luo H
Front Genet; 2020; 11():990. PubMed ID: 32983229
[TBL] [Abstract][Full Text] [Related]
25. Transfer of metastatic traits via miR-200c in extracellular vesicles derived from colorectal cancer stem cells is inhibited by atractylenolide I.
Tang D; Xu X; Ying J; Xie T; Cao G
Clin Transl Med; 2020 Aug; 10(4):e139. PubMed ID: 32898324
[TBL] [Abstract][Full Text] [Related]
26. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
27. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
28. TCF12 promotes the tumorigenesis and metastasis of hepatocellular carcinoma via upregulation of CXCR4 expression.
Yang J; Zhang L; Jiang Z; Ge C; Zhao F; Jiang J; Tian H; Chen T; Xie H; Cui Y; Yao M; Li H; Li J
Theranostics; 2019; 9(20):5810-5827. PubMed ID: 31534521
[TBL] [Abstract][Full Text] [Related]
29. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.
Gzil A; Zarębska I; Bursiewicz W; Antosik P; Grzanka D; Szylberg Ł
Mol Biol Rep; 2019 Dec; 46(6):6629-6645. PubMed ID: 31486978
[TBL] [Abstract][Full Text] [Related]
30. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4.
Yi L; Zhou X; Li T; Liu P; Hai L; Tong L; Ma H; Tao Z; Xie Y; Zhang C; Yu S; Yang X
J Exp Clin Cancer Res; 2019 Aug; 38(1):339. PubMed ID: 31382985
[TBL] [Abstract][Full Text] [Related]
31. SDF-1/CXCR4 axis enhances the immunomodulation of human endometrial regenerative cells in alleviating experimental colitis.
Li X; Lan X; Zhao Y; Wang G; Shi G; Li H; Hu Y; Xu X; Zhang B; Ye K; Gu X; Du C; Wang H
Stem Cell Res Ther; 2019 Jul; 10(1):204. PubMed ID: 31286993
[TBL] [Abstract][Full Text] [Related]
32. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
33. Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Lheureux S; Braunstein M; Oza AM
CA Cancer J Clin; 2019 Jul; 69(4):280-304. PubMed ID: 31099893
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention.
Antony J; Thiery JP; Huang RY
Phys Biol; 2019 May; 16(4):041004. PubMed ID: 30939460
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of CHIP promotes ovarian cancer metastasis by inducing Snail-mediated epithelial-mesenchymal transition.
Park SM; Park SH; Ryu KJ; Kim IK; Han H; Kim HJ; Kim SH; Hong KS; Kim H; Kim M; Cho BI; Heo JD; Kim NH; Hwang EM; Park JY; Yook JI; Cho HJ; Hwangbo C; Kim KD; Song H; Yoo J
Mol Oncol; 2019 May; 13(5):1280-1295. PubMed ID: 30927556
[TBL] [Abstract][Full Text] [Related]
36. Epithelial ovarian cancer.
Lheureux S; Gourley C; Vergote I; Oza AM
Lancet; 2019 Mar; 393(10177):1240-1253. PubMed ID: 30910306
[TBL] [Abstract][Full Text] [Related]
37. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
38. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
39. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
40. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
